In cancer, PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian and pancreatic cancers, and PRMT1 inhibition reduces the clonogenic growth of cancer cells exposed to low doses of cisplatin, sensitizing them to apoptosis (Giuliani et al, 2021; Ku et al, 2024; Matsubara et al, 2021; Nguyen et al, 2024). Here, PRMT1 is linked to pancreatic neoplasm.